Costes-Albrespic, M.; Liabeuf, S.; Larabi, I.-A.; Laville, S.M.; Stengel, B.; Omorou, A.Y.; Frimat, L.; Alvarez, J.-C.; Massy, Z.A.; Alencar de Pinho, N.;
et al. Furosemide and the Symptom Burden: The Potential Mediating Role of Uremic Toxins in Patients with CKD. Toxins 2025, 17, 541.
https://doi.org/10.3390/toxins17110541
AMA Style
Costes-Albrespic M, Liabeuf S, Larabi I-A, Laville SM, Stengel B, Omorou AY, Frimat L, Alvarez J-C, Massy ZA, Alencar de Pinho N,
et al. Furosemide and the Symptom Burden: The Potential Mediating Role of Uremic Toxins in Patients with CKD. Toxins. 2025; 17(11):541.
https://doi.org/10.3390/toxins17110541
Chicago/Turabian Style
Costes-Albrespic, Margaux, Sophie Liabeuf, Islam-Amine Larabi, Solène M. Laville, Bénédicte Stengel, Abdou Y. Omorou, Luc Frimat, Jean-Claude Alvarez, Ziad A. Massy, Natalia Alencar de Pinho,
and et al. 2025. "Furosemide and the Symptom Burden: The Potential Mediating Role of Uremic Toxins in Patients with CKD" Toxins 17, no. 11: 541.
https://doi.org/10.3390/toxins17110541
APA Style
Costes-Albrespic, M., Liabeuf, S., Larabi, I.-A., Laville, S. M., Stengel, B., Omorou, A. Y., Frimat, L., Alvarez, J.-C., Massy, Z. A., Alencar de Pinho, N., & the CKD-REIN Study Group.
(2025). Furosemide and the Symptom Burden: The Potential Mediating Role of Uremic Toxins in Patients with CKD. Toxins, 17(11), 541.
https://doi.org/10.3390/toxins17110541
